**Avastin® (bevacizumab) and PARP inhibitor approvals in ovarian cancer as of January 2019**

The following graphic illustrates where Avastin and PARP inhibitors are currently approved in ovarian cancer.1-4

### Indications

- **Avastin**, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.
- **Avastin**, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens.
- **Avastin**, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

### Boxed WARNINGS

- **Gastrointestinal (GI) perforation**
  - Serious and sometimes fatal GI perforation occurs at a higher incidence in Avastin-treated patients compared to patients treated with chemotherapy.
  - The incidence of GI perforation ranged from 0.3% to 3% across clinical studies.
  - Discontinue Avastin in patients with GI perforation.

- **Surgery and wound healing complications**
  - The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients.
  - Withhold Avastin for at least 28 days prior to elective surgery. Do not administer Avastin for at least 28 days after surgery and until the wound is fully healed.
  - Discontinue in patients with wound healing complications requiring medical intervention.

- **Hemorrhage**
  - Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemia, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin.
  - In clinical studies, the incidence of grade ≥3 hemorrhagic events among patients receiving Avastin ranged from 0.4% to 7%.
  - Do not administer Avastin to patients with serious hemorrhage or a recent history of hemoptysis (≥1/2 tsp of red blood).
  - Discontinue Avastin in patients who develop grade 3-4 hemorrhage.

---

**Please see reverse for Lynparza®, Zejula®, and Rubraca® indication statements.**

---

Please see accompanying full Prescribing Information, including **Boxed WARNINGS**, and reverse for additional important safety information.
Important safety information (continued)

Additional serious adverse events

- Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm vs chemotherapy arm included:
  - Non-GI fistulae (<1% to 1.8%, highest in patients with cervical cancer)
  - Arterial thromboembolic events (grade ≥3, 5%, highest in patients with GBM)
  - Renal injury and proteinuria
    - Grade 3–4 proteinuria ranged from 0.7% to 7% in clinical studies
    - Nephrotic syndrome (<1%)
- Additional serious adverse events with increased incidence in the Avastin-treated arm vs chemotherapy arm included:
  - Venous thromboembolism (grade ≥3, 11% seen in GOG-0240)
  - Hypertension (grade 3–4, 5%–18%)
  - Posterior reversible encephalopathy syndrome (PRES) (<0.5%)
  - Congestive heart failure (CHF): grade ≥3 left ventricular dysfunction (1%)
- Infusion reactions with the first dose of Avastin occurred in <3% of patients, and severe reactions occurred in 0.2% of patients
- Avoid use in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan or clinical symptoms of bowel obstruction
- Inform females of reproductive potential of the risk of ovarian failure prior to initiating treatment with Avastin

Pregnancy warning

- Based on the mechanism of action and animal studies, Avastin may cause fetal harm
- Advise female patients that Avastin may cause fetal harm, and to inform their healthcare provider of a known or suspected pregnancy
- Advise females of reproductive potential to use effective contraception during treatment with Avastin and for 6 months after the last dose of Avastin
- Advise nursing women not to breastfeed during treatment with Avastin and for 6 months following their last dose of treatment
- Avastin may impair fertility

Most common adverse events

- Across studies, the most common adverse reactions observed in Avastin patients at a rate >10% were:
  - Epistaxis
  - Headache
  - Hypertension
  - Rhinitis
- Across all studies, Avastin was discontinued in 8% to 22% of patients because of adverse reactions

Other Indications

Lynparza® (olaparib) is indicated

- for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA1-mutated (gBRCA1m or sBRCA1m) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients with gBRCA1m advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on an FDA-approved companion diagnostic for Lynparza.
- for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
- for the treatment of adult patients with deleterious or suspected deleterious germline BRCA1-mutated (gBRCA1m) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.

Rubraca® (rucaparib) is indicated

- for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
- for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca®

Zejula® (niraparib) is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Please see accompanying full Prescribing Information, including Boxed WARNINGS, and reverse for additional important safety information.


All trademarks and registered trademarks are the property of their respective owners.